As of June 2026, according to UNITED THERAPEUTICS's latest financial report, the company's current EPS (TTM) is $29.28. In 2025, the company recorded an earnings per share (EPS) of $30.13, which represents an increase compared to its EPS of $26.44 in 2024. UNITED THERAPEUTICS's earnings per share for the quarterly report ending on Mar 31, 2026 was $6.32.
The annual EPS in 2025 was $30.13, an increase of 14% from $26.44 in 2024. For the quarter ending Mar 31, 2026, the EPS was $6.32, showing a 12% decrease from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2026 is $29.28. In 2024, the annual EPS was $26.44, showing an increase of 25.7% from 2023.
UNITED THERAPEUTICS has recorded a decrease in EPS of 12% over the last 12 months (YoY, quarterly). For the last three years, UTHR recorded an average annual EPS growth rate of 23.5%. UNITED THERAPEUTICS had an average annual EPS growth rate of 20.9% over the last 5 years. Across the last decade, UTHR had an average annual EPS growth of 7.8%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| GILD Gilead Sciences Inc | 16.85 | 1,700% | 23.2% | 132.8% |
| UTHR UNITED THERAPEUTICS Corp | 18.59 | 14% | 23.5% | 20.9% |
| PFE Pfizer Inc | 18.87 | -3.5% | -37.4% | -3.7% |
| TEVA Teva Pharmaceutical Industries Ltd | 24.24 | 184.8% | N/A | N/A |
| CAH Cardinal Health Inc | 34.84 | 86.2% | N/A | N/A |
| LLY ELI LILLY & Co | 39.27 | 95.6% | 49.2% | 27.5% |
| BAX Baxter International Inc | N/A | -47.2% | N/A | N/A |
| CYTK Cytokinetics Inc | N/A | -24.3% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.